FormentiSC,ArslanAA,LoveSM, 2012.Global breast cancer: The lessons to bring home,Int J Breast Cancer 249501 -
ParveenS,SarwarG,KhuwajaM,AhmedR,NazeerM., 2011.Carcinoma of breast, pattern and presentation in developing countries,Pak J Surg 24 246 -9
OnitiloAA,EngelJM,GreenleeRT,MukeshBN, 2009.Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival,Clin Med Res 7 4 -13
SpitaleA,MazzolaP,SoldiniD,MazzucchelliL,BordoniA, 2009.Breast cancer classification according to immunohistochemical markers: Clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland,Ann Oncol 20 628 -35
PalaEE,BayolU,CumurcuS,KeskinE., 2012.Immunohistochemical characteristics of triple negative/basal-like breast cancer,Turk Patoloji Derg 28 238 -44
AkiyamaF,IwaseH, 2009.Triple negative breast cancer: Clinicopathological characteristics and treatment strategies,Breast Cancer 16 252 -3
SasakiY,Tsuda H, 2009.Clinicopathological characteristics of triplenegative breast cancers,Breast Cancer 16 254 -9
PengY., 2012.Potential prognostic tumor biomarkers in triplenegative breast carcinoma,Beijing Da Xue Xue Bao 44 666 -72
CheangMCU,VoducD,BajdikC,LeungS,McKinneyS,ChiaSK, 2008.Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype,Clin Cancer Res 14 1368 -76
RakhaEA,El-SayedME,GreenAR,LeeAHS,RobertsonJF,EllisIO, 2007.Prognostic markers in triple-negative breast cancer,Cancer 109 25 -32
FoleyJ,NickersonNK,NamS,AllenKT,GilmoreJL,NephewKP, 2010.EGFR signaling in breast cancer: Bad to the bone,Semin Cell Dev Biol 21 951 -60
ReganJL,KendrickH,MagnayF,VafaizadehV,GronerB,Smalley MJ, 2012.c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer,Oncogene 31 869 -83
CareyLA,RugoHS,MarcomPK,MayerEL,EstevaFJ,MaCX, 2008.EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer,J Clin Oncol 26 1009 -
CorkeryB,CrownJ,ClynesM,O'DonovanN., 2009.Epidermal growth factor receptor as a potential therapeutic target in triplenegative breast cancer,Ann Oncol 20 862 -7
SartorC,ZhouH,PerouCM,EthierSP, 2004.Basal-like breast tumor-derived cell lines are growth inhibited and radiosensitized by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Breast Cancer Res Treat 88 311 -
KandulaM,ChennaboinaKK,YsAR, 2013.Molecular mechanism and targeted therapy options of triple-negative (ER, PgR,Cancer: Review. World J Oncol 4 137 -41
FinnRS,BengalaC,IbrahimN,RochéH,SparanoJ,StraussLC, 2011.Dasatinib as a single agent in triple-negative breast cancer: Results of an open-label phase 2 study,Clin Cancer Res 17 6905 -13
KanapathyP,TaySK,NairA,LeongCO, 2012.Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women,BMC Clin Pathol 12 18 -
Giraldo-JiménezMY,CabanillasF,NegrónV,EcheniqueM,MojicaP,SantiagoK,RHealth Sci,J, 2012.Triple negative breast cancer: A retrospective study of Hispanics residing in Puerto Rico, 31 45 -51
SajidMT,AhmedM,AzharM,MustafaQ,ShukarI,AhmedM, 2014.Age related frequency of triple negative breast cancer in women,J Coll Physicians Surg Pak 24 400 -3
LermaE,PeiroG,RamónT,FernandezS,MartinezD,PonsC, 2007.Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas),Mod Pathol 20 1200 -7
ChoccalingamC,RaoL,RoaS.,Cancer, 2012.Clinicopathological characteristics of triple negative and non triple negative high grade breast carcinomas with and without basal marker (CK5/6 and EGFR) expression at a rural tertiary hospital in India, 6 21 -9
ZhuY,WangY,GuanB,RaoQ,WangJ,MaH, 2014.C-kit and PDGFRA gene mutations in triple negative breast cancer,Int J Clin Exp Pathol 7 4280 -5